<code id='436AF4F54C'></code><style id='436AF4F54C'></style>
    • <acronym id='436AF4F54C'></acronym>
      <center id='436AF4F54C'><center id='436AF4F54C'><tfoot id='436AF4F54C'></tfoot></center><abbr id='436AF4F54C'><dir id='436AF4F54C'><tfoot id='436AF4F54C'></tfoot><noframes id='436AF4F54C'>

    • <optgroup id='436AF4F54C'><strike id='436AF4F54C'><sup id='436AF4F54C'></sup></strike><code id='436AF4F54C'></code></optgroup>
        1. <b id='436AF4F54C'><label id='436AF4F54C'><select id='436AF4F54C'><dt id='436AF4F54C'><span id='436AF4F54C'></span></dt></select></label></b><u id='436AF4F54C'></u>
          <i id='436AF4F54C'><strike id='436AF4F54C'><tt id='436AF4F54C'><pre id='436AF4F54C'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:48
          The Chamber of Commerce in downtown Washington, DC.
          The U.S. Chamber of Commerce sued to stop a new Medicare drug price negotiation program from going into effect. Adobe

          WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday over whether drugmakers have enough say in Medicare’s new drug price negotiation program, in the first oral arguments in a lawsuit challenging the new law.

          The two sides debated two questions: whether the Chamber of Commerce would be sufficiently injured by the law to file a lawsuit, and whether the negotiation program was a violation of drugmakers’ due process rights.

          advertisement

          The hearing was held in the U.S. District Court for the Southern District of Ohio, and Judge Michael Newman, a Trump nominee, presided. Newman didn’t ask any questions of the attorneys, so the hearing didn’t provide any hints about which way he might be leaning on the issues.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Three issues to watch in global health in 2024
          Three issues to watch in global health in 2024

          ChristineKao/STATAsweenterthefifthyearofthischallengingdecade,lifefinallyappearstobeinchingtowardnor

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          The nurse manager staffing crisis is hurting patients

          JaeC.Hong/APThoughtheCovid-19pandemicbroughtheightenedattentiontonursesoverall,auniquenursingrolehas